ADAM17 and benign prostatic hyperplasia: The present study uncovers the functional correlation between COX-2–PGE2 and ADAM-17 in BPH, which may be a future target for the management of BPH while preserving the current level of testosterone and mitigating interference from anti-androgen therapy.